Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good day, and welcome to the ARS Pharmaceuticals Third Quarter ...

Amgen today announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of Rheumatology (ACR) Convergence 2024 conference in Washington, D.C., ...

Call today to schedule an appointment or fill out an online request form. If requested before 2 p.m. you will receive a response today.